Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PRISM BioLab Co. LTD ( (JP:206A) ) has issued an announcement.
PRISM BioLab reported first-quarter revenue of ¥132 million for the fiscal year ending September 30, 2026, a modest year-on-year increase, but remained in the red with an operating loss of ¥284 million and a net loss of ¥285 million. Earnings per share fell to a loss of ¥7.74, while the company’s equity ratio declined from 87.6% to 80.9%, reflecting a reduction in equity as losses widened.
Total assets decreased slightly to ¥3.0 billion at the end of December 2025, indicating some balance sheet erosion early in the fiscal year. The company maintained its policy of not paying dividends, confirmed a zero-dividend forecast for the current fiscal year, and declined to issue full-year earnings guidance, citing an inability to make a reasonable estimate at this time, which adds uncertainty for investors monitoring its financial trajectory.
The most recent analyst rating on (JP:206A) stock is a Hold with a Yen193.00 price target. To see the full list of analyst forecasts on PRISM BioLab Co. LTD stock, see the JP:206A Stock Forecast page.
More about PRISM BioLab Co. LTD
PRISM BioLab Co. LTD is a Japan-based biotechnology company listed on the Tokyo Stock Exchange. The company focuses on drug discovery and related bio-pharmaceutical research and development activities, targeting innovation-driven growth in the life sciences sector.
Average Trading Volume: 1,394,611
Technical Sentiment Signal: Buy
Current Market Cap: Yen7.17B
Find detailed analytics on 206A stock on TipRanks’ Stock Analysis page.